A 68-year-old man presents to the urology clinic with a 2-year history of progressive lower urinary tract symptoms. He reports nocturia 4–5 times per night, weak urinary stream, hesitancy, and incomplete emptying. Digital rectal examination reveals a smooth, firm, symmetrically enlarged prostate. Post-void residual urine is 120 mL. Serum PSA is 2.8 ng/mL. Uroflowmetry shows peak flow of 8 mL/s. He has no history of urinary tract infection, neurological disease, or prior urological surgery. What is the most appropriate first-line pharmacological treatment?

Explanation

## Diagnosis & Clinical Context This patient presents with **classic benign prostatic hyperplasia (BPH)** with lower urinary tract symptoms (LUTS) and objective evidence of obstruction: - Nocturia, weak stream, hesitancy, incomplete emptying - Smooth, symmetrically enlarged prostate on DRE - Elevated post-void residual (120 mL) - Reduced peak flow on uroflowmetry (8 mL/s; normal >15 mL/s) - Normal PSA excludes malignancy ## First-Line Pharmacotherapy for BPH **Key Point:** Alpha-1 adrenergic antagonists (α-blockers) are the gold standard first-line medical therapy for symptomatic BPH with LUTS. ### Mechanism & Rationale Alpha-blockers (e.g., tamsulosin, alfuzosin, doxazosin) work by: 1. Blocking α~1~-adrenergic receptors on prostatic smooth muscle 2. Causing rapid relaxation of the prostatic urethral smooth muscle 3. Reducing outlet obstruction and improving urinary flow 4. Providing symptom relief within **days to weeks** **Clinical Pearl:** Tamsulosin 0.4 mg once daily is preferred over other α-blockers because it is **uroselective** (selective for α~1A~ receptors in the prostate), resulting in fewer systemic side effects (hypotension, dizziness) compared to non-selective agents like doxazosin. ### Why α-Blockers First? | Feature | α-Blockers | 5α-Reductase Inhibitors | |---------|-----------|------------------------| | **Onset** | Days–weeks | 3–6 months | | **Symptom relief** | Excellent | Moderate | | **Effect on prostate size** | None | Reduces by ~25% | | **Best for** | Acute/moderate LUTS | Large prostate (>40 g) | | **First-line** | Yes | Second-line or combination | **High-Yield:** 5α-reductase inhibitors (finasteride, dutasteride) are **not** first-line monotherapy because they take 3–6 months to show benefit and are reserved for: - Large prostates (>40 g on ultrasound) - Recurrent hematuria from BPH - Combination therapy with α-blockers in moderate-to-severe cases ## Treatment Algorithm ```mermaid flowchart TD A[BPH with LUTS]:::outcome --> B{Prostate size & severity?}:::decision B -->|Small/moderate, moderate LUTS| C[Alpha-blocker monotherapy]:::action B -->|Large prostate >40g OR recurrent hematuria| D[5-alpha reductase inhibitor]:::action B -->|Moderate-severe, large prostate| E[Alpha-blocker + 5-alpha inhibitor]:::action C --> F[Symptom relief in 1-4 weeks]:::outcome D --> G[Symptom relief in 3-6 months]:::outcome E --> H[Combined benefit over 3-6 months]:::outcome ``` **Mnemonic:** **ALPHA FIRST** = Alpha-blockers are First-line In Routine Symptomatic Treatment of BPH Hyperplasia ## Why Other Options Are Incorrect - **Finasteride:** Correct class (5α-reductase inhibitor) but **not first-line monotherapy** because onset is slow (3–6 months) and this patient needs rapid symptom relief. Reserved for large glands or combination therapy. - **Oxybutynin:** An anticholinergic agent used for **overactive bladder / detrusor overactivity**, not outlet obstruction from BPH. Will worsen urinary retention in this patient. - **Ciprofloxacin:** An antibiotic with no role in uncomplicated BPH. Indicated only if UTI is suspected (no fever, pyuria, or dysuria here). [cite:Harrison 21e Ch 297]